Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies.

× No keyword cloud information.

6 in total

1. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

Authors: Susan O'Brien; David A Rizzieri; Norbert Vey; Farhad Ravandi; Utz O Krug; Mikkael A Sekeres; Mike Dennis; Adriano Venditti; Donald A Berry; Tove Flem Jacobsen; Karin Staudacher; Trygve Bergeland; Francis J Giles
Journal: Br J Haematol Date: 2012-06-15 Impact factor: 6.998

Review 2. Novel therapeutics in acute myeloid leukemia.

Authors: Kendra Sweet; Jeffrey E Lancet
Journal: Curr Hematol Malig Rep Date: 2014-06 Impact factor: 3.952

3. Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

Authors: Francis Giles; David Rizzieri; Farhad Ravandi; Ronan Swords; Tove Flem Jacobsen; Susan O'Brien
Journal: Leuk Res Date: 2012-01-09 Impact factor: 3.156

Review 4. Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Authors: Lindsay A M Rein; David A Rizzieri
Journal: Ther Adv Hematol Date: 2014-12

Review 5. Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?

Authors: Alice Mims; Robert K Stuart
Journal: Curr Hematol Malig Rep Date: 2013-06 Impact factor: 3.952

Review 6. Improving nucleoside analogs via lipid conjugation: Is fatter any better?

Authors: Peter Alexander; Gregory Kucera; Timothy S Pardee
Journal: Crit Rev Oncol Hematol Date: 2016-01-21 Impact factor: 6.312

6 in total